NASH

Targeting the complexities of NASH

There are currently no approved treatments for nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and diagnosis remains challenging. But studies show that fat and scar tissue can leave the liver, suggesting that NAFLD and NASH are reversible.

That's where we can help - Revvity offers a comprehensive portfolio of tools to enable further understanding of NASH pathophysiology, aid in the development of NASH diagnostic solutions for the assessment of NASH, help identify new therapeutic targets, and characterize novel drug therapies.

For research use only. Not for use in diagnostic procedures.

Explore our solutions

マイクロプレートリーダー

Revvityのプレートリーダー製品群は、今日のラボの多様なアッセイ要件に対応する最新の検出技術を備えています。

Learn more

Cellular Imaging & Analysis

Answer complex cell biology questions with powerful cellular imaging and analysis solutions, including systems, reagents, microplates, software and automation.

Learn more

In Vivo Imaging

Track, monitor, and visualize biological processes and disease progression with our industry-leading in vivo imaging systems and reagents.

Learn more

マイクロプレート

適切なマイクロプレートを選択することは、アッセイにおいて非常に重要ですが、見落とされがちです。正しいマイクロプレートは貴重なデータを提供するのに役立ちますが、間違ったマイクロプレートはデータの欠落や不正確さを招き、プロジェクトのタイムラインや最終的なコストの上昇につながります。

Learn more | View products

Platforms & Automation

At Revvity, we are increasing access to healthcare technology with a full range of scalable platforms to serve all laboratories.

Learn more

Radiometric Detectors

Radiometric detection has long been and remains today as the gold standard used by researchers in many scientific applications such as analyzing drug pathways, protecting lab environments, assessing environmental contamination, and monitoring food safety.

Learn more